Crossmark

Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma

Published Online: 2024-11-12

Published Print: 2025-02

Authors

Zhang, Xiaotian

Xu, Kailin https://orcid.org/0000-0003-1375-1084
Gale, Robert Peter

Pan, Bin https://orcid.org/0000-0002-2697-8985
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82370218, 82341203)
License Information

Text and Data Mining valid from 2024-11-12

Version of Record valid from 2024-11-12
More Information

Article History

Received: 4 July 2024

Revised: 29 October 2024

Accepted: 31 October 2024

First Online: 12 November 2024

Competing interests

: RPG is a consultant to Antengene Biotech LLC; Medical Director, FFF Enterprises Inc.; A speaker for Janssen Pharma and Hengrui Pharma; Board of Directors: Russian Foundation for Cancer Research Support and Scientific Advisory Board, StemRad Ltd.

Document is current